Comparative Pharmacology
Head-to-head clinical analysis: OSIMERTINIB MESYLATE versus TIBSOVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OSIMERTINIB MESYLATE versus TIBSOVO.
OSIMERTINIB MESYLATE vs TIBSOVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Osimertinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that selectively inhibits EGFR exon 19 deletion and L858R substitution mutations, as well as T790M resistance mutations, with less activity against wild-type EGFR.
Isocitrate dehydrogenase-2 (IDH2) inhibitor; targets mutant IDH2 isoforms to reduce 2-hydroxyglutarate (2-HG) levels, promoting myeloid differentiation.
80 mg orally once daily, with or without food.
500 mg orally once daily taken with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 48 hours (range 36-60 h) based on population pharmacokinetic analysis, supporting once-daily dosing.
Terminal elimination half-life: 50-60 hours, supporting once-daily dosing with steady-state reached in approximately 2 weeks.
Osimertinib is eliminated primarily via feces (67.8%, with 1.2% as unchanged drug) and urine (13.8%, with 0.8% as unchanged drug). The remainder is recovered as metabolites.
Primarily hepatic metabolism (CYP3A4) and fecal excretion (77% unchanged and metabolites); renal elimination accounts for <1% of absorbed dose.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent